Concepedia

Author

Rachael Brake

Amgen (United States)

Also Known As

RACHAEL BRAKE, Rachael Brake, Rachael L Brake, Rachael L. Brake

76

Publications

398

Citations

11

H-Index

33

Concepts

All Affiliations

Amgen (United States)Millennium Engineering and Integration (United States)Takeda (United States)Takeda (Japan)The Kids Research Institute Australia
RB

About

Rachael Brake is an author at Amgen (United States) specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

134

2

Natural Sciences

2

2

61

3

Cell Biology

2

2

35

4

Biochemistry

1

1

37

5

Chemical Biology

1

1

37

Rachael Brake

×

12

Publications

331

Citations

11

H-Index

YearCitations

Targeting <i>HER2</i> Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Han Han, Shuai Li, Ting Chen,

Cancer Research

2021

54

The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Richard T. Lewis, Christiane Bode, Deborah M. Choquette,

Journal of Medicinal Chemistry

2012

43

Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors

Marian C. Bryan, Douglas A. Whittington, Elizabeth M. Doherty,

Journal of Medicinal Chemistry

2012

37

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

Anna Hernández‐Prat, Alejo Rodríguez‐Vida, Núria Juanpere,

Molecular Cancer Research

2019

30

NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis

Joachim R. Göthert, Rachael Brake, Monique Smeets,

Blood

2007

29

Effects of Palifermin on Antitumor Activity of Chemotherapeutic and Biological Agents in Human Head and Neck and Colorectal Carcinoma Xenograft Models

Rachael Brake, Charlie Starnes, John Lu,

Molecular Cancer Research

2008

28

Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling

Dean Bottino, Mayankbhai Patel, Ekta Kadakia,

Clinical Cancer Research

2019

25

Multiple negative elements contribute to repression of the HOX11 proto-oncogene

Rachael Brake, Ursula R. Kees, Paul M. Watt

Oncogene

1998

24

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.

Jeffrey R. Infante, Josep Tabernero, Andrés Cervantes,

Molecular Cancer Therapeutics

2013

19

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Steven Zhang, Shu Jin, Celina Griffin,

Clinical Pharmacology in Drug Development

2021

16

Page 1